A61P 35 - Antineoplastic agents

Patents for A61P 35 - Antineoplastic agents (221,099)
03/2011
03/24/2011	US20110070270 Immunostimulating agent
03/24/2011	US20110070269 Lipopolysaccharide isolated from pyrularia tissue and/or pyrularia-associated bacteria and uses thereof
03/24/2011	US20110070268 Method
03/24/2011	US20110070262 Viral Vectors and Their Use in Therapeutic Methods
03/24/2011	US20110070253 Tumour-associated peptides binding to mhc molecules
03/24/2011	US20110070252 Mage-a3/hpv 16 peptide vaccines for head and neck cancer
03/24/2011	US20110070251 Cancer vaccine composition
03/24/2011	US20110070250 Therapeutical Composition Containing Dentritic Cells and use Thereof
03/24/2011	US20110070248 Dr5 ligand drug conjugates
03/24/2011	US20110070246 Antibodies Against CDCP1 for the Treatment of Cancer
03/24/2011	US20110070245 Imp-1 oncogene as a therapeutic target and prognostic indicator for lung cancer
03/24/2011	US20110070244 Methods for the treatment of multiple myeloma
03/24/2011	US20110070243 Compositions and methods for the treatment of tumor of hematopoietic
03/24/2011	US20110070240 Methods of treating b-cell cancers
03/24/2011	US20110070233 Actriib antagonists and dosing and uses thereof
03/24/2011	US20110070232 Combination Therapy with an Antitumor Alkaloid
03/24/2011	US20110070221 Gnaq mutations in melanoma
03/24/2011	US20110070218 Methods of treating cancer of the central nervous system
03/24/2011	US20110070215 Methods of treating cancer using neurotrophin retargeted endopeptidases
03/24/2011	US20110070212 Methods of Treating Cancer Using Glucagon-Like Hormone Retargeted Endopeptidases
03/24/2011	US20110070211 Methods of Treating Cancer Using Galanin Retargeted Endopepidases
03/24/2011	US20110070208 Hbv epitope reactive exogenous t cell receptor (tcr) and uses thereof
03/24/2011	US20110070201 Mucosal or enteral administration of biologically active macromolecules
03/24/2011	US20110070200 Abrogating proinflammatory cytokine production during oncolytic reovirus therapy
03/24/2011	US20110070192 Method of preparation of novel nucleoside analogs and uses
03/24/2011	US20110070191 T cell receptor fusions and conjugates and methods of use there of
03/24/2011	US20110070188 Bab triblock polymers having improved release characteristics
03/24/2011	US20110070186 Methods of Treating Cancer Using Growth Factor Retargeted Endopeptidases
03/24/2011	US20110070163 Cancer cell migration and cancer cell invasion inhibitor
03/24/2011	US20110070162 Rna interference mediating small rna molecules
03/24/2011	US20110070159 Compositions comprising red microalgae polysaccharides and metals
03/24/2011	US20110070156 Combining Radioimmunotherapy and Antibody-Drug Conjugates for Improved Cancer Therapy
03/24/2011	US20110070155 Anti-CD74 Immunoconjugates and Methods
03/24/2011	DE102010044516A1 Hemmung des Überlebens von Lymphom durch Cyclohexenonverbindungen aus Antrodia camphorata Inhibition of survival of lymphoma cyclohexenone from Antrodia camphorata by
03/24/2011	CA2812158A1 Bisphosphonate-prostatic acid phosphatase inhibitor conjugates to treat prostate cancer bone metastasis
03/24/2011	CA2774732A1 Dosage regimen for administering an epcamxcd3 bispecific antibody
03/24/2011	CA2774669A1 Oxaliplatin nanoparticles and method for preparing same
03/24/2011	CA2774645A1 Pharmaceutical composition for peroral administration of 3,3'-diindolylmethane
03/24/2011	CA2774460A1 Inhibition of endosomal toll-like receptor activation
03/24/2011	CA2774367A1 Novel compounds and therapeutic use thereof for protein kinase inhibition
03/24/2011	CA2774327A1 Pharmaceutical compositions which inhibit fkbp52-mediated regulation of androgen receptor function and methods of using same
03/24/2011	CA2774260A1 Class i anti-cea antibodies and uses thereof
03/24/2011	CA2774148A1 Tricyclic compounds and pharmaceutical uses thereof
03/24/2011	CA2774015A1 Treatment of cancer
03/24/2011	CA2773125A1 Compounds having tafia inhibitory activity
03/24/2011	CA2772777A1 Methods for treating brain tumors
03/24/2011	CA2772314A1 Pharmaceutical combination for treating tumor
03/24/2011	CA2771984A1 Abt-263 crystalline forms and solvates for use in treating bcl-2 protein related diseases
03/24/2011	CA2771336A1 Synergistic anti-cd47 therapy for hematologic cancers
03/24/2011	CA2771176A1 Macrocyclic inhibitors of jak
03/23/2011	EP2299272A2 N-terminally truncated HER-2/NEU protein as a cancerprognostic indicator
03/23/2011	EP2298927A2 Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
03/23/2011	EP2298897A1 Regulation of oncogenes by microRNAs
03/23/2011	EP2298878A2 Compositions and methods for the diagnosis of cancer
03/23/2011	EP2298877A1 Compounds for immunotherapy of prostate cancer and methods for their use
03/23/2011	EP2298816A2 Apoptosis induced by an antibody against Her2
03/23/2011	EP2298815A1 B-cell reduction using CD37-specific and CD20-specific binding molecules
03/23/2011	EP2298803A2 Human G-protein coupled receptor and ligands thereof
03/23/2011	EP2298780A1 Antitumoral derivatives of Ecteinascidin ET-743
03/23/2011	EP2298778A1 Imidazothiazole derivative having 4,7-diazaspiroý2.5¨octane ring structure
03/23/2011	EP2298770A1 Heterocyclic compounds as TrkA modulators
03/23/2011	EP2298748A2 Triazole compounds that modulate HSP90 activity
03/23/2011	EP2298746A1 4-amino- quinazoline and quinoline derivatives having an inhibitory effect on signal transduction mediated by tyrosine kinases
03/23/2011	EP2298355A2 Albumin fusion proteins
03/23/2011	EP2298354A2 Remodelling and glycoconjugation of interferon-beta
03/23/2011	EP2298350A2 Composition comprising an inducing agent and an anti-viral agent for the treatment of viral disorders
03/23/2011	EP2298346A2 Human antibodies specific to kdr and uses thereof
03/23/2011	EP2298339A1 Treating neoplasms with neurotoxin
03/23/2011	EP2298334A2 Tweak receptor
03/23/2011	EP2298333A2 Tweak receptor
03/23/2011	EP2298332A1 BAFF, inhibitors thereof and their use in the modulation of the B-cell response
03/23/2011	EP2298327A1 Anti-tumor agent
03/23/2011	EP2298309A1 Antitumor agent, kit and method of treating cancer
03/23/2011	EP2298308A2 Integrin-binding small molecules
03/23/2011	EP2298305A1 4-(N-Phenylamino)-quinazolines/quinolines as inhibitors of tyrosine kinases
03/23/2011	EP2298304A2 Carboline derivatives useful in the treatment of cancer
03/23/2011	EP2298300A1 Compositions for inhibition of anglogenesis comprising thalidomide and aspirin
03/23/2011	EP2298299A2 O-methylated rapamycin derivatives for alleviation and inhibition of lymphoproliferative disorders
03/23/2011	EP2298298A2 Use of AT-1 receptor antagonist or AT-2 receptor modulator for treating diseases associated with an increase of AT-1 or AT-2 receptors
03/23/2011	EP2298292A2 Kinase inhibitors for treating cancers
03/23/2011	EP2298291A2 Kinase inhibitors for treating cancers
03/23/2011	EP2298074A2 Facially amphiphilic polymers and oligomers, compositions thereof, and use thereof in methods of treating cancer
03/23/2011	EP2297206A1 Anti-cxcr4 antibodies
03/23/2011	EP2297183A1 Treatment for diseases relying on discovery that thioredoxin mediates nitric oxide release in cells
03/23/2011	EP2297156A1 Substituted quinazolines and their uses for myeoloprolific and thrombotic diseases
03/23/2011	EP2297153A1 Limk2 inhibitors, compositions comprising them, and methods of their use
03/23/2011	EP2297151A1 Inhibitors of protein kinases
03/23/2011	EP2297148A1 Novel derivatives of (bridged piperazinyl)-1-alcanone and use thereof as p75 inhibitors
03/23/2011	EP2297145A2 Polymorphs of 5-(3-(ethylsulfonyl)phenyl)-3,8-dimethyl-n- (1-methylpiperidin-4-yl)-9h-pyrido[2, 3-b]indole-7-carboxamide and methods of use therefor
03/23/2011	EP2297138A1 Processes for the preparation of crystalline forms of sunitinib malate
03/23/2011	EP2297115A2 Quinazoline derivatives
03/23/2011	EP2297106A1 Phenoxypyridinylamide derivatives and their use in the treatment of pde4 mediated disease states
03/23/2011	EP2297105A1 Substituted amides, method of making, and use as btk inhibitors
03/23/2011	EP2297103A1 Hydroxyphenylsulfonamides as antiapoptotic bcl inhibitors
03/23/2011	EP2297075A1 Dihydro-iso-ca-4 and analogues: potent cytotoxics, inhibitors of tubulin polymerization
03/23/2011	EP2296706A2 Photochemical internalisation of kinase inhibitors
03/23/2011	EP2296705A1 Ccl20-specific antibodies for cancer therapy
03/23/2011	EP2296697A1 Immunogenic peptides derived from the midkine protein, as an anticancer vaccine
03/23/2011	EP2296679A1 Abrogating proinflammatory cytokine production during oncolytic reovirus therapy
03/23/2011	EP2296678A1 Modulating interstitial pressure and oncolytic viral delivery and distribution

1 ... 550 551 552 553 554 555 556 557 558 559 560 561 562 563 564 565 566 567 568 569 570 ... 2211